Compare Stocks

2 / 10
Try these comparisons:

Stock Comparison

PHG vs BSX

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
PHG
Koninklijke Philips N.V.

Medical - Devices

HealthcareNYSE • NL
Market Cap$25.84B
5Y Perf.-34.1%
BSX
Boston Scientific Corporation

Medical - Devices

HealthcareNYSE • US
Market Cap$84.08B
5Y Perf.+48.9%

PHG vs BSX — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
PHG logoPHG
BSX logoBSX
IndustryMedical - DevicesMedical - Devices
Market Cap$25.84B$84.08B
Revenue (TTM)$17.83B$20.07B
Net Income (TTM)$895M$2.89B
Gross Margin45.2%69.0%
Operating Margin8.0%19.8%
Forward P/E17.5x16.7x
Total Debt$8.09B$12.42B
Cash & Equiv.$2.79B$2.04B

PHG vs BSXLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

PHG
BSX
StockMay 20May 26Return
Koninklijke Philips… (PHG)10065.9-34.1%
Boston Scientific C… (BSX)100148.9+48.9%

Price return only. Dividends and distributions are not included.

Quick Verdict: PHG vs BSX

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: BSX leads in 5 of 7 categories, making it the strongest pick for growth and revenue expansion and valuation and capital efficiency. Koninklijke Philips N.V. is the stronger pick specifically for dividend income and shareholder returns and recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
PHG
Koninklijke Philips N.V.
The Income Pick

PHG is the clearest fit if your priority is income & stability.

  • Dividend streak 1 yrs, beta 1.12, yield 1.5%
  • 1.5% yield; 1-year raise streak; the other pay no meaningful dividend
  • +17.7% vs BSX's -46.0%
Best for: income & stability
BSX
Boston Scientific Corporation
The Growth Play

BSX carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.

  • Rev growth 19.9%, EPS growth 55.2%, 3Y rev CAGR 16.5%
  • 155.5% 10Y total return vs PHG's 48.3%
  • Lower volatility, beta 0.34, Low D/E 50.7%, current ratio 1.62x
Best for: growth exposure and long-term compounding
See the full category breakdown
CategoryWinnerWhy
GrowthBSX logoBSX19.9% revenue growth vs PHG's -1.0%
ValueBSX logoBSXLower P/E (16.7x vs 17.5x)
Quality / MarginsBSX logoBSX14.4% margin vs PHG's 5.0%
Stability / SafetyBSX logoBSXBeta 0.34 vs PHG's 1.12, lower leverage
DividendsPHG logoPHG1.5% yield; 1-year raise streak; the other pay no meaningful dividend
Momentum (1Y)PHG logoPHG+17.7% vs BSX's -46.0%
Efficiency (ROA)BSX logoBSX6.9% ROA vs PHG's 3.4%, ROIC 8.8% vs 6.4%

PHG vs BSX — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

PHGKoninklijke Philips N.V.

Segment breakdown not available.

BSXBoston Scientific Corporation
FY 2025
Cardiovascular
66.0%$13.3B
MedSurg
34.0%$6.8B

PHG vs BSX — Financial Metrics

Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLPHGLAGGINGBSX

Income & Cash Flow (Last 12 Months)

BSX leads this category, winning 5 of 6 comparable metrics.

BSX and PHG operate at a comparable scale, with $20.1B and $17.8B in trailing revenue. BSX is the more profitable business, keeping 14.4% of every revenue dollar as net income compared to PHG's 5.0%. On growth, BSX holds the edge at +15.9% YoY revenue growth, suggesting stronger near-term business momentum.

MetricPHG logoPHGKoninklijke Phili…BSX logoBSXBoston Scientific…
RevenueTrailing 12 months$17.8B$20.1B
EBITDAEarnings before interest/tax$2.5B$4.7B
Net IncomeAfter-tax profit$895M$2.9B
Free Cash FlowCash after capex$755M$3.6B
Gross MarginGross profit ÷ Revenue+45.2%+69.0%
Operating MarginEBIT ÷ Revenue+8.0%+19.8%
Net MarginNet income ÷ Revenue+5.0%+14.4%
FCF MarginFCF ÷ Revenue+4.2%+18.1%
Rev. Growth (YoY)Latest quarter vs prior year+1.1%+15.9%
EPS Growth (YoY)Latest quarter vs prior year+2.1%+18.5%
BSX leads this category, winning 5 of 6 comparable metrics.

Valuation Metrics

PHG leads this category, winning 4 of 6 comparable metrics.

At 24.9x trailing earnings, PHG trades at a 15% valuation discount to BSX's 29.2x P/E. On an enterprise value basis, PHG's 10.7x EV/EBITDA is more attractive than BSX's 25.3x.

MetricPHG logoPHGKoninklijke Phili…BSX logoBSXBoston Scientific…
Market CapShares × price$25.8B$84.1B
Enterprise ValueMkt cap + debt − cash$32.1B$94.5B
Trailing P/EPrice ÷ TTM EPS24.85x29.16x
Forward P/EPrice ÷ next-FY EPS est.17.55x16.75x
PEG RatioP/E ÷ EPS growth rate
EV / EBITDAEnterprise value multiple10.70x25.30x
Price / SalesMarket cap ÷ Revenue1.23x4.19x
Price / BookPrice ÷ Book value/share2.02x3.46x
Price / FCFMarket cap ÷ FCF24.62x22.99x
PHG leads this category, winning 4 of 6 comparable metrics.

Profitability & Efficiency

BSX leads this category, winning 6 of 8 comparable metrics.

BSX delivers a 12.4% return on equity — every $100 of shareholder capital generates $12 in annual profit, vs $8 for PHG. BSX carries lower financial leverage with a 0.51x debt-to-equity ratio, signaling a more conservative balance sheet compared to PHG's 0.74x.

MetricPHG logoPHGKoninklijke Phili…BSX logoBSXBoston Scientific…
ROE (TTM)Return on equity+8.2%+12.4%
ROA (TTM)Return on assets+3.4%+6.9%
ROICReturn on invested capital+6.4%+8.8%
ROCEReturn on capital employed+7.1%+11.1%
Piotroski ScoreFundamental quality 0–977
Debt / EquityFinancial leverage0.74x0.51x
Net DebtTotal debt minus cash$5.3B$10.4B
Cash & Equiv.Liquid assets$2.8B$2.0B
Total DebtShort + long-term debt$8.1B$12.4B
Interest CoverageEBIT ÷ Interest expense4.34x11.03x
BSX leads this category, winning 6 of 8 comparable metrics.

Total Returns (Dividends Reinvested)

PHG leads this category, winning 4 of 6 comparable metrics.

A $10,000 investment in BSX five years ago would be worth $13,117 today (with dividends reinvested), compared to $5,734 for PHG. Over the past 12 months, PHG leads with a +17.7% total return vs BSX's -46.0%. The 3-year compound annual growth rate (CAGR) favors PHG at 11.6% vs BSX's 2.1% — a key indicator of consistent wealth creation.

MetricPHG logoPHGKoninklijke Phili…BSX logoBSXBoston Scientific…
YTD ReturnYear-to-date+0.3%-40.3%
1-Year ReturnPast 12 months+17.7%-46.0%
3-Year ReturnCumulative with dividends+38.8%+6.5%
5-Year ReturnCumulative with dividends-42.7%+31.2%
10-Year ReturnCumulative with dividends+48.3%+155.5%
CAGR (3Y)Annualised 3-year return+11.6%+2.1%
PHG leads this category, winning 4 of 6 comparable metrics.

Risk & Volatility

Evenly matched — PHG and BSX each lead in 1 of 2 comparable metrics.

BSX is the less volatile stock with a 0.34 beta — it tends to amplify market swings less than PHG's 1.12 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. PHG currently trades 81.2% from its 52-week high vs BSX's 51.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricPHG logoPHGKoninklijke Phili…BSX logoBSXBoston Scientific…
Beta (5Y)Sensitivity to S&P 5001.12x0.34x
52-Week HighHighest price in past year$33.44$109.50
52-Week LowLowest price in past year$21.95$54.98
% of 52W HighCurrent price vs 52-week peak+81.2%+51.7%
RSI (14)Momentum oscillator 0–10047.733.2
Avg Volume (50D)Average daily shares traded1.0M15.5M
Evenly matched — PHG and BSX each lead in 1 of 2 comparable metrics.

Analyst Outlook

PHG leads this category, winning 1 of 1 comparable metric.

Wall Street rates PHG as "Hold" and BSX as "Buy". PHG is the only dividend payer here at 1.47% yield — a key consideration for income-focused portfolios.

MetricPHG logoPHGKoninklijke Phili…BSX logoBSXBoston Scientific…
Analyst RatingConsensus buy/hold/sellHoldBuy
Price TargetConsensus 12-month target$91.33
# AnalystsCovering analysts2243
Dividend YieldAnnual dividend ÷ price+1.5%
Dividend StreakConsecutive years of raises10
Dividend / ShareAnnual DPS$0.34
Buyback YieldShare repurchases ÷ mkt cap0.0%0.0%
PHG leads this category, winning 1 of 1 comparable metric.
Key Takeaway

PHG leads in 3 of 6 categories (Valuation Metrics, Total Returns). BSX leads in 2 (Income & Cash Flow, Profitability & Efficiency). 1 tied.

Best OverallKoninklijke Philips N.V. (PHG)Leads 3 of 6 categories
Loading custom metrics...

PHG vs BSX: Frequently Asked Questions

10 questions · data-driven answers · updated daily

01

Is PHG or BSX a better buy right now?

For growth investors, Boston Scientific Corporation (BSX) is the stronger pick with 19.

9% revenue growth year-over-year, versus -1. 0% for Koninklijke Philips N. V. (PHG). Koninklijke Philips N. V. (PHG) offers the better valuation at 24. 9x trailing P/E (17. 5x forward), making it the more compelling value choice. Analysts rate Boston Scientific Corporation (BSX) a "Buy" — based on 43 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — PHG or BSX?

On trailing P/E, Koninklijke Philips N.

V. (PHG) is the cheapest at 24. 9x versus Boston Scientific Corporation at 29. 2x. On forward P/E, Boston Scientific Corporation is actually cheaper at 16. 7x — notably different from the trailing picture, reflecting expected earnings growth.

03

Which is the better long-term investment — PHG or BSX?

Over the past 5 years, Boston Scientific Corporation (BSX) delivered a total return of +31.

2%, compared to -42. 7% for Koninklijke Philips N. V. (PHG). Over 10 years, the gap is even starker: BSX returned +155. 5% versus PHG's +48. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — PHG or BSX?

By beta (market sensitivity over 5 years), Boston Scientific Corporation (BSX) is the lower-risk stock at 0.

34β versus Koninklijke Philips N. V. 's 1. 12β — meaning PHG is approximately 225% more volatile than BSX relative to the S&P 500. On balance sheet safety, Boston Scientific Corporation (BSX) carries a lower debt/equity ratio of 51% versus 74% for Koninklijke Philips N. V. — giving it more financial flexibility in a downturn.

05

Which is growing faster — PHG or BSX?

By revenue growth (latest reported year), Boston Scientific Corporation (BSX) is pulling ahead at 19.

9% versus -1. 0% for Koninklijke Philips N. V. (PHG). On earnings-per-share growth, the picture is similar: Koninklijke Philips N. V. grew EPS 224. 0% year-over-year, compared to 55. 2% for Boston Scientific Corporation. Over a 3-year CAGR, BSX leads at 16. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — PHG or BSX?

Boston Scientific Corporation (BSX) is the more profitable company, earning 14.

4% net margin versus 5. 0% for Koninklijke Philips N. V. — meaning it keeps 14. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BSX leads at 19. 8% versus 8. 0% for PHG. At the gross margin level — before operating expenses — BSX leads at 69. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is PHG or BSX more undervalued right now?

On forward earnings alone, Boston Scientific Corporation (BSX) trades at 16.

7x forward P/E versus 17. 5x for Koninklijke Philips N. V. — 0. 8x cheaper on a one-year earnings basis.

08

Which pays a better dividend — PHG or BSX?

In this comparison, PHG (1.

5% yield) pays a dividend. BSX does not pay a meaningful dividend and should not be held primarily for income.

09

Is PHG or BSX better for a retirement portfolio?

For long-horizon retirement investors, Boston Scientific Corporation (BSX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

34), +155. 5% 10Y return). Both have compounded well over 10 years (BSX: +155. 5%, PHG: +48. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between PHG and BSX?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: PHG is a mid-cap quality compounder stock; BSX is a mid-cap high-growth stock. PHG pays a dividend while BSX does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.

Stocks Like

PHG

Stable Dividend Mega-Cap

  • Sector: Healthcare
  • Market Cap > $100B
  • Net Margin > 5%
  • Dividend Yield > 0.5%
Run This Screen
Stocks Like

BSX

High-Growth Compounder

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 7%
  • Net Margin > 8%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform PHG and BSX on the metrics below

Revenue Growth>
%
(PHG: 1.1% · BSX: 15.9%)
Net Margin>
%
(PHG: 5.0% · BSX: 14.4%)
P/E Ratio<
x
(PHG: 24.9x · BSX: 29.2x)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.